Phase i study of the infectivity, safety and immunogenicity of a recombinant, live-attenuated, bovine/human, parainfluenza virus type 3 (b/HPIV3) vector vaccine expressing the spike glycoprotein of…
Ended Awarded Last action
- Contract number
- 75N93023F00003
- Awardee
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $100,615
Award facts
- Contract value 100% obligated
- $100,615.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Baltimore, MD 21205, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$959,582 | |
| Original award | $1,060,197 |
About this award
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $100,615 cost-no-fee delivery order contract to The Johns Hopkins University to conduct a Phase I study on the infectivity, safety, and immunogenicity of a recombinant, live-attenuated, bovine/human, parainfluenza virus type 3 (B/hPIV3) vector vaccine expressing the SARS-CoV-2 spike glycoprotein, administered nasally. This contract, which has a period of performance ending on September 30, 2024, is not set aside for any specific business category. The Johns Hopkins University, a private non-profit research university, has extensive experience supporting federal agencies like the NIAID, Centers for Disease Control and Prevention (CDC), Department of Defense (DoD), and Department of Justice (DoJ) through prime and subcontracts for biomedical research, public health initiatives, and scientific analysis.
Description
Phase i study of the infectivity, safety and immunogenicity of a recombinant, live-attenuated, bovine/human, parainfluenza virus type 3 (b/HPIV3) vector vaccine expressing the spike glycoprotein of sars-COV-2, delivered by nasal spray to HPIV3-seropo
Quick answers
Who was awarded contract 75N93023F00003?
75N93023F00003 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2023.
How much is contract 75N93023F00003 worth?
The government has obligated $100,615 on 75N93023F00003.
Is contract 75N93023F00003 an order under another contract?
Yes. 75N93023F00003 is a delivery order under 75N93019D00031, an indefinite delivery contract.
Was contract 75N93023F00003 competed?
The extent of competition for 75N93023F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award